Sponsor Study ID:
A Phase 3, Randomized, Double blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III IV Melanoma (RELATIVITY 098)
The purpose of this study is to assess relatlimab and nivolumab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.
(MUSC NetID required for document access)
For more information about the trial above please contact the study team: